Anyone following RAP. They have recently partnered with Coviu, who are in their early seed rounds. One might assume some combined market strength once Coviu IPO's. Risks may be consumers' unwillingness to take up telehealth and likewise resistance from doctors who are quite comfortable (excluding further lockdowns) in the face to face model they are used to. Any thoughts?
ResApp Health grants cough counting SDK licence to AstraZeneca Japan for asthma patient support program
Pre-Submission package lodged with the US FDA
Brisbane, Australia, 10 February 2021 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that it has filed a Pre-Submission package with the United States (US) Food and Drug Administration (FDA) and requested a meeting with the agency to progress the potential clearance of a prescription-only software as a medical device application to detect lower respiratory tract illness in children and adults.